Spots Global Cancer Trial Database for Efficacy Study of IL-21 to Treat Metastatic Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy Study of IL-21 to Treat Metastatic Melanoma
Official Title: An Open-label, Dose Escalation Safety and Tolerability Study of Recombinant Human Interleukin-21 (Phase 1) Followed by an Open-label Treatment Study (Phase 2a) in Patients With Stage IV Malignant Melanoma
Study ID: NCT00336986
Interventions
Study Description
Brief Summary: This trial is conducted in Oceania. A phase 2a study to assess the effect on tumor size. At least 14 to a maximum of 40 patients, who have not previously received treatment for their stage IV disease, will be treated for 6 weeks. IL-21 will be administered intravenously.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novo Nordisk Investigational Site, Box Hill, , Australia
Novo Nordisk Investigational Site, East Melbourne, , Australia
Novo Nordisk Investigational Site, Heidelberg, , Australia
Novo Nordisk Investigational Site, Malvern, , Australia
Novo Nordisk Investigational Site, Nedlands, , Australia
Novo Nordisk Investigational Site, Parkville, , Australia
Novo Nordisk Investigational Site, Westmead, , Australia
Contact Details
Name: Global Clinical Registry (GCR; 1452)
Affiliation: Novo Nordisk A/S
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
